Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Neoplasm Metastasis

Neurofibromatoses

Neurofibromatosis 1

Neurofibromatosis

Neurofibromatosis Type 1

Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.

Subjects will receive Abemaciclib 150 mg orally twice daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.

Abemaciclib

Subjects will recieve LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.

LY3214996

Anita Turk, MD

The purpose of CTO-IUSCC-0730 study is to assess the clinical efficacy of LY3214996 in combination with abemaciclib at the recommended phase 2 dose of LY3214996 200 mg orally daily and abemaciclib 150 mg orally twice daily. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1.

the number of patients who achieve a best overall response of complete response (CR) or partial response (PR) divided by the total number of patients treated (safety population)

CTCAE Version 5.0 will be used to summarize adverse events in the assessment of safety for incorporating LY3214996 in combination with abemaciclib. Summaries of treatment related adverse events in the population will be tabulated. All adverse events (AEs) will be presented in incidence tables coded by CTC term.

measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented

the time from the date of start of treatment to the first date of the observed clinical or radiologically documented PD or death due to any cause, whichever occurs first. For patients who are not known to have died or progressed as of the data-inclusion cut-off date, PFS time will be censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systematic anticancer therapy.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.	NCT04534283	Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat...	Abemaciclib LY3214996	18 Years -	Indiana University
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.	NCT04534283	Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat...	Abemaciclib LY3214996	18 Years -	Indiana University

Spots Global Cancer Trial Database for point mutation